B. Brans et al., ACTIVITY OF I-123 METAIODOBENZYLGUANIDINE IN CHILDHOOD NEUROBLASTOMA - LACK OF RELATION TO TUMOR DIFFERENTIATION IN-VIVO, European journal of nuclear medicine, 25(2), 1998, pp. 144-149
Neuroblastoma (NB) tumour cells have a remarkable tendency to differen
tiate spontaneously or under the influence of certain drugs. it is not
clear whether metaiodobenzylguanidine, (MIBG) uptake correlates with
differentiation of NE cells, In 28 tumours of 26 patients, iodine-123
MIBG uptake in primary NBs was studied in relation to tumour different
iation, tumour size, cell density and degree of necrosis in subsequent
ly resected specimens, Genetic features such as the presence of chromo
somal aberrations (1p-deletion and MYCN amplification) and/or P-glycop
rotein (mdr-1 gene product) were also evaluated in relation to MIBG up
take, A highly variable and unpredictable intensity of MIBG uptake was
observed in primary as well as secondary resected tumours. This inten
sity did not relate to any of the above-mentioned factors except that
there was a trend towards more intense uptake with increasing size of
the tumour, We conclude from our observations that, in contrast to com
monly held opinion, well-differentiated tumours do not a priori show a
lower MIBG uptake in vivo, even when there are a low number of viable
cells and a high degree of necrosis. The degree of differentiation or
tumour viability and necrosis following longstanding chemotherapeutic
treatment cannot be predicted by the MIBG scan findings, The observed
MIBG uptake may be importantly influenced by factors other than those
associated with cellular differentiation.